Search

Search Constraints

You searched for: Author/Creator Daniele, Gennaro

Search Results

1. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. (June 2017)

2. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Issue 1 (December 2016)

3. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Issue 1 (December 2016)

4. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. (September 2019)

5. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Issue 10 (October 2013)

6. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. (January 2016)

7. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Issue 2 (February 2011)

8. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. Issue 6 (30th April 2021)

9. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO‐16A/MaNGO‐OV2A study. Issue 6 (June 2021)

10. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. Issue 3 (March 2023)